Answers are grounded in this paper and cite their sources.
Observational analysis shows prolonged progression-free survival in patients with gut microbiota modulation, indicating CAR T-cell potency enhancement.
Supplementary Fig. 1: Patient Flow Diagram. Supplementary Fig. 2: Akkermansia muciniphila positive patients present a prolonged PFS and higher gut microbial diversity. Supplementary Fig. 3: Bioactivity of the CD19/CD28-ζ CAR-T cells in our mouse model. Supplementary Fig. 4: Exploration of TME in B-cell lymphoma patients receiving CD19 CAR-T cells. Supplementary Fig. 5: Comprehensive phenotypic characterization of CAR-T cells infiltrating organs in our immunocompetent mouse model. Supplementary Fig. 6: Characterization of bone marrow composition in B-cell lymphoma patients receiving CD19 CAR-T cells. Supplementary Fig. 7: Akkermansia spp. fails to translocate to distal organs. Supplementary Fig. 8: Tryptophan-derived indoles in mice and patients treated with CAR-T cell therapy. Supplementary Fig. 9: Graphical abstract.
No takes yet. Share an insight, caveat, or question.
Marcos-Kovandzic et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: